SCHEMBL5237189

SCHEMBL5237189

CCCCOc1c(CCl)n(CCC)c(=O)c2ccc(Cl)cc12

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 7/20 0.50
RORA P35398 1/20 0.41
RORC P51449 1/20 0.41
NR1H2 P55055 1/20 0.41
RORB Q92753 1/20 0.41
PLK1 P53350 1/20 0.39
TSHR P16473 2/20 0.38
ALDH1A1 P00352 1/20 0.38
HTT P42858 1/20 0.38
HSD17B10 Q99714 1/20 0.38
RXFP1 Q9HBX9 1/20 0.38
L3MBTL1 Q9Y468 2/20 0.37
TDP1 Q9NUW8 1/20 0.37
GABRA1 P14867 2/20 0.36
GABRG2 P18507 2/20 0.36
GABRB3 P28472 2/20 0.36
GABRA5 P31644 2/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
ADORA2A P29274 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5233023 0.89 DPP4 (0.49) DPP4RORARORCNR1H2RORB
Hydrochloric Acid SCHEMBL5240215 0.88 DPP4 (0.59) DPP4RORARORCNR1H2RORB
SCHEMBL5237536 0.88 DPP4 (0.44) DPP4RORARORCNR1H2RORB
SCHEMBL5240942 0.84 DPP4 (0.47) DPP4RORARORCNR1H2RORB
SCHEMBL5239586 0.83 SMN1; SMN2 (0.48) DPP4RORARORCNR1H2RORB
SCHEMBL5236683 0.81 DPP4 (0.45) DPP4RORARORCNR1H2RORB
SCHEMBL5236813 0.81 DPP4 (0.46) DPP4RORARORCNR1H2RORB
SCHEMBL6110347 0.81 DPP4 (0.44) DPP4RORARORCNR1H2RORB
SCHEMBL5235448 0.80 DPP4 (0.44) DPP4RORARORCNR1H2RORB
SCHEMBL5235047 0.79 ALDH1A1 (0.44) DPP4RORARORCNR1H2RORB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1355886-B1 FUSED HETEROCYCLIC COMPOUNDS TAKEDA PHARMACEUTICAL (JP) 2007-07-11 EP disclosed
US-7034039-B2 Fused heterocyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-04-25 US disclosed
US-20040082607-A1 Fused heterocyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-04-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040082607-A1 Fused heterocyclic compounds DPP7, DPP4, METAP1 DPP4 2/4885RORA 2682/4885RORC 2671/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.